CANCER GENETICS, INC. (NASDAQ:CGIX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 30, 2018, the Board of Directors of Cancer Genetics, Inc. (“Cancer Genetics” or the “Company”) appointed John A. Roberts as the Company’s Chief Executive Officer and President. Mr. Roberts had been serving as the Company’s Chief Executive Officer on an interim basis since February 2, 2018 in addition to his role as our Chief Operating Officer and Executive Vice President, Finance, a position he has held since he joined the Company in July 2016.
Prior to joining Cancer Genetics, from August 1, 2015 to June 30, 2016, Mr. Roberts served as the Chief Financial Officer for VirMedica, Inc., an innovative technology solutions company that provides an end-to-end platform that enables specialty drug manufacturers and pharmacies to optimize product commercialization and management. Prior to VirMedica, from August 1, 2011 to July 31, 2015, Mr. Roberts was the Chief Financial and Administrative Officer for AdvantEdge Healthcare Solutions, a global healthcare analytics and services organization. Prior to that, Mr. Roberts was the Chief Financial Officer and Treasurer for InfoLogix, Inc., a publicly-traded healthcare-centric mobile software and solutions provider. He has also held CFO roles at leading public medical device and healthcare services firms including Clarient, Inc., a publicly-traded provider of diagnostic laboratory services and Daou Systems, Inc., a publicly-traded healthcare IT software development and services firm. In addition, he has held key senior executive roles with MEDecision, Inc., HealthOnline, Inc. and the Center for Health Information. Mr. Roberts earned a Bachelor of Science and a Master’s degree in Business Administration from the University of Maine. He is Chairman of the Board of Directors for the Drug Information Association (DIA), a global neutral forum enabling drug developers and regulators access to insights and collaboration.
Mr. Roberts will continue to be compensated to the terms of his employment agreement dated as of July 11, 2016, subject to further review by the compensation committee of the board. The description of his employment agreement is set forth in the Company’s definitive proxy statement filed on April 21, 2017 and incorporated herein by reference.
There are no transactions between Mr. Roberts and the Company that would be reportable under Item 404(a) of Regulation S-K.
About CANCER GENETICS, INC. (NASDAQ:CGIX)
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.
